Vaccines for parasitic infections

Vaccination against worm parasites of animals

The 1990s have seen the culmination of decades of painstaking research with the registration and launch of Tickgard (Hoechst), a recombinant vaccine against Boophilus microplus, and the provisional registration of a Taenia ovis vaccine. Research continues to hold promise for immunological control of Echinococcus, Fasciola, Haemonchus, Trichostrongylus and Ostertagia. Blood-sucking parasites (e.g. ticks and H. contortus) are susceptible to control by vaccines containing 'novel' or 'concealed' antigens where serum antibodies in blood meals attack targets in the gut. Antibodies also provide protection in taeniid models, whereas the protective response to be sought in Fasciola remains unclear. More problematic are formulations and delivery strategies to induce expulsion of gastrointestinal nematodes, using vaccines containing recombinant 'conventional' antigens. The use of computer models to simulate vaccine efficacy in worm control and challenges to the concept of 'hypo-responsiveness' of young lambs will encourage cautious optimism and lively debate as to the prospects for integrated worm control using parasite vaccines. This review covers the aspirations, current success and problems faced by researchers in the parasite arena.

Vaccination against animal parasites

A decade of molecular parasitology is beginning to bear fruit, with the appearance of several new, highly effective, practical vaccines against parasitic diseases. Recombinant antigen vaccines have been developed against cestode, nematode, trematode, protozoan and arthropod parasites. Greatest progress has been made with veterinary vaccines, where the ability to test numerous vaccine formulations in challenge trials has allowed more rapid identification of host-protective antigens than is possible with many medically important parasites. Several quite different approaches to vaccine development have been successful. The traditional approach using live, attenuated parasites continues to provide effective vaccines against several protozoan and nematode parasites. Recombinant DNA technology, monoclonal antibody technology, protein chemistry and immunochemistry have played critical roles in the outstanding success which has been achieved over the last 5 years in the development of defined-antigen vaccines. Two approaches have been successful in research towards defined antigen vaccines against parasites: (1) the 'natural antigen' approach where immune responses are stimulated to parasite molecules which are normally antigenic, and possibly host-protective, in infected hosts; (2) the 'naive antigen' approach where parasite molecules which are not antigenic, or of very low antigenicity, in infected hosts are used to raise immune responses capable of killing the parasite. This review examines the successful approaches taken towards the development of effective anti-parasite vaccines and the vaccines which have been produced to date.

Immunization against geographical isolates of Trichinella spiralis in mice

Partially purified antigen preparations from six isolates of Trichinella spiralis were used to immunize mice. Immunogenicity of the antigens was assessed in terms of antibody and lymphocyte responses and ability to stimulate protective immunity against challenge. Isolate antigens showed considerable cross-reactivity, and all elicited protective responses. Two major patterns of immunizing ability could be distinguished: (a) isolates that immunized well against heterologous challenge and elicited good immunity in London isolate-immunized mice (C-76 and Laso), and (b) isolates that immunized poorly against heterologous challenge and were least effective in London isolate-immunized mice (GM-1 and Mad-83). The immunogenicity of one isolate (C-76) was markedly greater than the others, inducing rapid loss in unvaccinated mice, almost complete protection in London isolate-immunized mice, and immunity in London isolate-challenged mice equivalent to the homologous antigen. These variations in immunogenicity, cross-reactivity and immunizing ability are discussed in terms of constraints that may operate against the development and use of vaccines against parasites that are widely distributed geographically.